2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 503

Safety Update On Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure
Abstract Number: 196

Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy
Abstract Number: 1320

Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Abstract Number: 1337

Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis
Abstract Number: 346

Sclerostin Protects Against Inflammatory Bone Loss by Regulating Tnfalpha Mediated p38-Mapkinase Activation
Abstract Number: 1023

Scoring Radiographic Progression in Axial Spa: Should We Use the Modified Stoke in Ankylosing Spondylitis Spine Score or the Radiographic Ankylosing Spondylitis Spinal Score?
Abstract Number: 2442

Screening of Osteoporosis in Men Age 70 and Older: A Need for Increased Awareness
Abstract Number: 39

SDF-1 Induces Osteoclastogenesis in Rheumatoid Arthritis by Upregulating of RANKL Expression in Synovial Fibroblasts and CD4+ T Cells
Abstract Number: 1055

Sec61 Is Indispensable for Antigen Cross-Presentation and the Development of Lupus Nephritis: A Novel ‘Self-Organized Criticality Theory’ Explaining the Cause of Systemic Lupus Erythematosus (SLE)
Abstract Number: 2191

Secretagogue Use in Patients with Primary Sjogren’s Syndrome
Abstract Number: 2302

Secreted Frizzled-Related Protein 4 Induces a Profibrotic Phenotype in Systemic Sclerosis Fibroblasts by Activating a Non-Canonical WNT Signaling Pathway
Abstract Number: 443

Secreted Frizzled-Related Protein 5 Exerts the Anti-Inflammatory Role in Rheumatoid Arthritis Via Down-Regulation of c-Jun N-Terminal Kinase
Abstract Number: 919

Sedentary Time, Physical Activity, and Concurrent Blood Pressure in Osteoarthritis Initiative Participants
Abstract Number: 1008

Segmentation and Quantification of Bone Erosions in the Hands of Patients with Rheumatoid Arthritis Using High Resolution Computed Tomography
Abstract Number: 740

Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].